Neutralizing vaccination against viral interleukin-6 from a primate rhadinovirus

Huynh, K. N.; LeSon, J.; Kalavacherla, S.; Hartigan-O'Connor, D. P.; Dutra, J.; Chin, N.; Le, V.; Andal, D. R.; Fontaine, J.; Chang, W. L. W.; Deere, J. D.

doi:10.64898/2026.10.26.761420

bioRxiv · 10.64898/2026.10.26.761420

Neutralizing vaccination against viral interleukin-6 from a primate rhadinovirus

Huynh, K. N.·LeSon, J.·Kalavacherla, S.·Hartigan-O'Connor, D. P.·Dutra, J.·Chin, N.·Le, V.·Andal, D. R.·Fontaine, J.·Chang, W. L. W.·Deere, J. D.

View original source ↗Export metadata ↓

Abstract

Herpesviruses are ancient viruses that devote a significant fraction of their protein-coding potential to interference with host immunity. Diverse herpesviruses encode proteins with similarity to host MHC molecules, interferon regulatory factors, complement regulators, G-protein coupled receptors, chemokines, and cytokines. Certain gammaherpesviruses, including Kaposi sarcoma-associated herpesvirus (KSHV) and rhesus rhadinovirus (RRV), encode viral cytokines similar to host IL-6, called viral IL-6 (vIL-6). The potential of vIL-6 to act as a protective vaccine antigen against these rhadinoviruses remains under-explored. We isolated a new RRV strain, which encodes virion surface proteins similar to those of previous isolates and a vIL-6 that is nearly identical. We found that, although unmodified vIL-6 is a poor immunogen eliciting low neutralizing titers, vIL-6-Fc fusion protein elicits high-titer responses after either one or two doses. We detected no adverse effects related to cytokine activity, nor interference with concomitantly administered vaccine against the RRV glycoprotein B. Our results demonstrate an approach for eliciting neutralizing antibodies against a highly conserved viral protein that contributes to rhadinovirus persistence and oncogenesis.

Explore related subjects

immunology Preprint

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Huynh, K. N., LeSon, J., Kalavacherla, S., Hartigan-O'Connor, D. P., Dutra, J., Chin, N., Le, V., Andal, D. R., Fontaine, J., Chang, W. L. W., Deere, J. D.. 2026-10-30. Neutralizing vaccination against viral interleukin-6 from a primate rhadinovirus. https://doi.org/10.64898/2026.10.26.761420

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

Distinct profiles and antibody production by splenic and lymph node antibody-secreting cells in Trypanosoma cruzi infection

Evidence from bone marrow and intestinal lamina propria studies indicates that antibody-secreting cell (ASC) characteristics are shaped by the local microenvironment; yet whether secondary lymphoid organs harbor distinct ASC populations during infection remains unclear. Here, we investigated plasmablasts (PB) from the spleen and inguinal lymph nodes (LN) in acute Trypanosoma cruzi infection. Although PB from both tissues expressed canonical ASC markers, they displayed distinct transcriptional, phenotypic, and functional profiles. Splenic PB upregulated genes and proteins associated with inflammation, immunomodulation, and B-cell interactions. Activated and naive B cells also exhibited tissue-specific transcriptional programs, suggesting that local cues influence B-cell differentiation. Consistent with these differences, spleens from infected mice contained more T follicular helper cells, whereas LN were enriched in regulatory T cells. High-dimensional flow cytometry identified multiple PB subsets differentially represented between tissues. Functionally, splenic PB secreted higher levels of IgM, IgA, and IgG, including both parasite-specific and autoreactive antibodies. In contrast, LN PB preferentially produced IgG against peptide 72 of the shed acute-phase antigen (SAPA), despite lower overall T. cruzi-specific antibody production. These findings demonstrate that secondary lymphoid organs harbor distinct PB populations adapted to their local microenvironments during acute infection

immunology↗

bioRxiv2026

Intrinsic immune receptor triggering mechanism informs rational chimeric receptor design

The T cell receptor (TCR) couple antigen recognition to T-cell activation and immune homeostasis. As an eight-subunit assembly, TCR activation operates as a highly coordinated, multi-subunit signaling event. However, which subunit serves as the primary trigger upon ligand engagement still remains unresolved. we identify CD3{varepsilon} as a triggering subunit whose intracellular domain (ICD) is released from the plasma membrane during TCR activation. Elevated membrane tension facilitates this transition from a membrane-proximal to a membrane-distal conformation. The released ICD forms condensates through phase separation with free or co-receptor-associated Lck. These condensates recruit additional CD3{varepsilon} ICDs from neighboring TCRs, triggering resting receptors and promoting further recruitment of TCRs and Lck to amplify proximal signaling. The CD3{varepsilon} ICD alone support robust T cell activation independently of its own ITAM. We observe a similar triggering mechanism in several activating receptors in T and nature killer (NK) cell. These findings support a unifying model in which designated subunits initiate multi-subunit immune receptor activation through phase separation with key kinases. Guided by this model, we engineered triggering molecules (TRIG) that lack canonical intracellular signaling modules. These TRIG molecules recruit endogenous immune receptors in a ligand-dependent manner and efficiently activate both T cells and NK cells. This mechanism provides a basis for designing chimeric receptors that activate immune cells through endogenous receptor signaling.

immunology↗

bioRxiv2026

CD4 T cell surface architecture is associated with response to anti-PD-1 therapy in non-small cell lung cancer

Anti-PD-1 therapy has substantially improved outcomes for patients with advanced non-small cell lung cancer (NSCLC), but clinical responses remain highly heterogeneous and are difficult to predict. Current immune profiling approaches primarily characterize immune cell composition and protein abundance, whereas the spatial organization of proteins at the cell surface has remained largely unexplored. Here, we demonstrate for the first time that cell surface protein organization is associated with clinical response to immune checkpoint inhibition therapy. Using the Proximity Network Assay (PNA), we simultaneously quantified cell frequencies, protein abundance, and protein organization in pretreatment peripheral blood mononuclear cells from 62 patients with advanced NSCLC treated with anti-PD-1 agents. While most cell populations were unchanged between responders and non-responders, pronounced response-associated alterations were identified within the CD4 T-cell compartment. Responders exhibited elevated expression of adhesion-associated proteins, and remodeling of a CD5-containing membrane domain. Increased colocalization within this domain was associated with poor clinical outcome and reduced survival. Machine learning analysis further identified CD4 T cell features as the strongest predictors of treatment response and demonstrated that protein organization provided greater predictive power than protein abundance alone. Together, these findings identify cell surface protein organization as a previously unexplored source of biomarkers and highlight its potential to improve immune profiling and biomarker discovery in cancer immunotherapy.

immunology↗